Neuphoria Therapeutics Inc. Increase (Decrease) in Deferred Liabilities
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Deferred Liabilities of -$139.17 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for the quarter ending 2026-06-30 was -$34.79K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for the quarter ending 2026-03-31 was -$34.79K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for the quarter ending 2025-12-31 was -$34.79K, a 400.02% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for the quarter ending 2025-09-30 was -$34.79K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for fiscal 2026 was -$139.17K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for fiscal 2025 was -$468.43K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for fiscal 2024 was -$139.17K.
- Neuphoria Therapeutics Inc. increase (decrease) in deferred liabilities for fiscal 2023 was -$139.17K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$69.59K derived: sum of 2 quarters · filed 2026-09-18 | -$104.38K derived: sum of 3 quarters · filed 2026-09-18 | -$139.17K 10-K · filed 2026-09-18 |
| 2026-03-31 | -$34.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$69.59K derived: sum of 2 quarters · filed 2026-05-15 | -$104.38K 10-Q · filed 2026-05-15 | -$371.00K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$34.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$69.59K 10-Q · filed 2026-02-17 | -$336.21K derived: sum of 3 quarters · filed 2026-09-18 | -$417.39K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$34.79K 10-Q · filed 2025-11-14 | -$301.42K derived: sum of 2 quarters · filed 2026-09-18 | -$382.60K derived: sum of 3 quarters · filed 2026-09-18 | -$371.00K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$266.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$347.81K derived: sum of 2 quarters · filed 2026-09-18 | -$336.21K derived: sum of 3 quarters · filed 2026-09-18 | -$468.43K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$81.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$69.59K derived: sum of 2 quarters · filed 2026-05-15 | -$201.80K 10-Q · filed 2026-05-15 | -$236.60K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $11.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$120.62K 10-Q · filed 2026-02-17 | -$155.41K derived: sum of 3 quarters · filed 2026-02-17 | -$190.21K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$132.22K 10-Q · filed 2025-11-14 | -$167.01K derived: sum of 2 quarters · filed 2025-11-14 | -$201.80K derived: sum of 3 quarters · filed 2025-11-14 | -$236.60K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$34.79K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$69.59K derived: sum of 2 quarters · filed 2025-09-29 | -$104.38K derived: sum of 3 quarters · filed 2025-09-29 | -$139.17K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$34.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$69.59K derived: sum of 2 quarters · filed 2025-05-20 | -$104.38K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$34.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$69.59K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$34.79K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$139.17K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |